A $92 million investment in adMare BioInnovations will help translate health research into innovative new therapies in Canada
March 30, 2022 - Vancouver, British Columbia
Protecting the health and safety of Canadians and making sure we have the domestic capacity to respond to future health crises are top priorities of the Government of Canada. With the guidance of Canada's Biomanufacturing and Life Sciences Strategy, the government is actively supporting the growth of a strong, competitive domestic life sciences sector, with cutting-edge biomanufacturing capabilities.
Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced a $92 million investment in adMare BioInnovations to drive company innovation, scale-up and training activities in Canada's life sciences sector. This investment will help translate commercially promising health research into innovative new therapies and will see Canadian anchor companies provide the training required and drive the growth of Canada's life science companies.
Through adMare's innovation centres in Vancouver and Montréal, entrepreneurs, academic researchers, innovators and emerging Canadian small and medium-sized enterprises (SME) can access a full spectrum of services, including scientific expertise, research infrastructure and business development support, as well as funding for new research and development projects with strong commercial potential.
Canada is growing its diverse talent pipeline and research systems while attracting industry leaders to transform innovative ideas into the scientific discoveries of tomorrow. The government will continue to focus on improving the health outcomes of Canadians, relaunching the economy and providing well-paying jobs to Canadians.
